Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2481184 | 0.85 | CHRM4 (0.31) | CHRM4 | |
| SCHEMBL22289740 | 0.79 | — | — | |
| SCHEMBL3799258 | 0.77 | MPO (0.36) | — | |
| SCHEMBL1099775 | 0.73 | ADORA2A (0.48) | — | |
| SCHEMBL3344379 | 0.73 | SMN1; SMN2 (0.32) | — | |
| SCHEMBL27243812 | 0.72 | — | — | |
| SCHEMBL147219 | 0.71 | SLC9A1 (0.43) | — | |
| SCHEMBL15515411 | 0.68 | IDO1 (0.31) | — | |
| SCHEMBL15516710 | 0.68 | ADORA2A (0.31) | — | |
| SCHEMBL1197168 | 0.68 | KDR (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10842803-B2 | Imidazopyridines Syk inhibitors | Kronos Bio, Inc. (US) | 2020-11-24 | — | — | US | claimed |
| EP-2373318-B1 | IMIDAZOPYRAZINE SYK INHIBITORS | GILEAD CONNECTICUT INC (US) | 2019-06-05 | — | — | EP | claimed |
| US-20190117679-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | Kronos Bio, Inc. | 2019-04-25 | — | — | US | claimed |
| US-10092583-B2 | Imidazopyridines Syk inhibitors | GILEAD CONNECTICUT, INC. (US) | 2018-10-09 | — | — | US | claimed |
| US-10093684-B2 | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors | GILEAD CONNECTICUT, INC. (US) | 2018-10-09 | — | — | US | claimed |
| US-20170121350-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2017-05-04 | — | — | US | claimed |
| US-20170095490-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | Kronos Bio, Inc. | 2017-04-06 | — | — | US | claimed |
| US-9562056-B2 | Imidazopyridines Syk inhibitors | GILEAD CONNECTICUT, INC. (US) | 2017-02-07 | — | — | US | claimed |
| US-8962835-B2 | Imidazopyrazine Syk inhibitors | GILEAD CONNECTICUT, INC. (US) | 2015-02-24 | — | — | US | claimed |
| EP-2545052-B1 | IMIDAZOPYRIDINES SYK INHIBITORS | GILEAD CONNECTICUT INC (US) | 2014-11-12 | — | — | EP | claimed |
| US-20140148430-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2014-05-29 | — | — | US | claimed |
| US-20130310363-A1 | IMIDAZOPYRIZINE SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2013-11-21 | — | — | US | claimed |
| US-20130231330-A1 | IMIDAZOPYRIZINE SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2013-09-05 | — | — | US | claimed |
| US-20130210802-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | Gilead Connecticut, Inc (US) | 2013-08-15 | — | — | US | claimed |
| US-8440667-B2 | Imidazopyrazine Syk inhibitors | GILEAD CONNECTICUT, INC. (US) | 2013-05-14 | — | — | US | claimed |
| EP-2545052-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | Gilead Connecticut, Inc. (US) | 2013-01-16 | — | — | EP | claimed |
| EP-2373318-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Gilead Connecticut, Inc. (US) | 2011-10-12 | — | — | EP | claimed |
| WO-2011112995-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-09-15 | — | — | WO | claimed |
| WO-2010068258-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | WO | claimed |
| US-20100152159-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2010-06-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190117679-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | SYK, BTK, ZAP70 | CHRM4 3279/4885 |
| US-10092583-B2 | Imidazopyridines Syk inhibitors | SYK, BTK, ZAP70 | CHRM4 3279/4885 |
| US-20170095490-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | SYK, BTK, ZAP70 | CHRM4 3279/4885 |
| US-10093684-B2 | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors | SYK, BTK, ZAP70 | CHRM4 4228/4885 |
| US-20130310363-A1 | IMIDAZOPYRIZINE SYK INHIBITORS | SYK, BTK, ZAP70 | CHRM4 3692/4885 |
| US-20130231330-A1 | IMIDAZOPYRIZINE SYK INHIBITORS | SYK, ZAP70, BTK | CHRM4 3358/4885 |
| US-20130210802-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | SYK, BTK, ZAP70 | CHRM4 2930/4885 |
| US-20170121350-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | CHRM4 3860/4885 |
| US-20140148430-A1 | IMIDAZOPYRIDINES SYK INHIBITORS | SYK, BTK, ZAP70 | CHRM4 2930/4885 |
| US-20100152159-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | CHRM4 3860/4885 |
| US-10842803-B2 | Imidazopyridines Syk inhibitors | SYK, BTK, ZAP70 | CHRM4 3279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.